-
1Academic Journal
Συγγραφείς: Yu. E. Dobrokhotova, L. V. Saprykina, N. A. Litvinova, Yu. N. Zadonskay, Ю. Э. Доброхотова, Л. В. Сапрыкина, Н. А. Литвинова, Ю. Н. Задонская
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 5, No 1 (2011); 15-17 ; Акушерство, Гинекология и Репродукция; Vol 5, No 1 (2011); 15-17 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: Люкрин-депо, matrix metalloproteinases, Lucrin Depot, матриксные металлопротеиназы
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/265/370; Болиева Г.У. Доброкачественные заболевания молочных желез при гиперпластических процессах эндо-и миометрия. Автореф. дис. …к.м.н. -Душанбе, 2006. -16 с.; Бохман Я.В. Руководство по онкогинекологии. Ст-Петербург, Фолиант, 2002, 542 с.; Задонская Ю.Н., Гиперпластические процессы эндометрия в пременопаузе: современные аспекты патогенеза и лечения.//Автореф. дисс. к. м. н. -М., 2008. -25 с; Литвинова Н.А. Состояние эндометрия у больных с сочетанной патологией эндо-и миометрия, перенесших эмболизацию маточных артерий в пременопаузальном периоде//Автореф. дисс. канд. мед. наук. М., 2009. -28 с.; Серов В.Н., Прилепская В.Н., Пшеничникова Т.Я. Гинекологическая эндокринология. Москва, Медицина, 1993, 499 с.; Curry T.E., Osteen K.G. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr. Rev., 2003, Vol. 24, N 4, P. 428-465.; Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front. Biosci., 2006, N 11, P. 1696-1701.; https://www.gynecology.su/jour/article/view/265
Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/265
-
2Academic Journal
Συγγραφείς: B. Ya. Alekseev, A. D. Kaprin, K. M. Nyushko, Б. Я. Алексеев, А. Д. Каприн, К. М. Нюшко
Πηγή: Cancer Urology; Том 7, № 1 (2011); 57-61 ; Онкоурология; Том 7, № 1 (2011); 57-61 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2011-7-1
Θεματικοί όροι: Люкрин депо®, hormone therapy, luteinizing-hormone-releasing hormone analogues, Lucrin depot®, гормональная терапия, аналоги ЛГРГ
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/100/115; Ries L.A.G., Kosary C.L., Hankey B.F. et al. (eds). SEER Cancer Statistics Review 1973–1995 Bethesda, MD: National Cancer Institute, 1998.; Чиссов В.И., Старинский В.В., Петрова Г. В. Злокачественные новообразования в России в 2007 году. М., 2009.; Матвеев В.Б. Клиническая онкоурология. М., 2003; с. 525–70.; Heidenreich A., Varga Z., Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2003;169(3):1090.; Partin A.W., Kattan M.W., Subong E.N. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277(18):1445–51.; Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941;385–402.; Daneshgari F., Crawford E.D. Endocrine herapy of advanced carcinoma of the prostate. Cancer 1993;71:1089–97.; Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–8.; Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937–6.; Pilepich M.V., Winter K., John M.J. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 200;50(5):1243–52.; Pilepich M.V., Winter K., Lawton C.A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285–90.; Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472–9.; Seruga B., Tannock I.F. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008;5(10):574–6.; Labrie F., Belanger A., Dupont A. et al. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993;16(6):475–92.; Chrisp P., Sorkin E.M. Leuprorelin:a review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging 199;1:487–509.; Sharifi R., Ratanwong C., Jung A. et al. Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv Drug Deliv Rev 1997;28:121–36. [PubMed]; Togushi H. Formulation study of leuprorelin acetate to improve clinical performance. Clin Ther 1992;14:121–30.; Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533–6.; Tunn U.W., Wiedey K. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis 2009;12(1):83–7.; Berges R., Bello U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 2006;22(4):649–55.; Tunn U.W., Kurek R., Renneberg H. et al. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35 (Suppl 1):27–31.; Gleave M.E., Goldenberg S.L., Chin J.L. et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001 Aug;166(2):500–6.; Soloway M.S., Pareek K., Sharifi R. et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167(1):112–6.; Montgomery B.S., Borwell J.P., Higgins D.M. Does needle size matters? Patient experience with luteinizing hormone releasing hormone analogue. Prostate Cancer Prostatic Dis 2005;8:66–8.; Heyns C.F., Simonin M.P., Grosgurin P. et al. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003;92(3):226–31.; https://oncourology.abvpress.ru/oncur/article/view/100
-
3Academic Journal
Συγγραφείς: Доброхотова, Ю., Сапрыкина, Л., Литвинова, Н., Задонская, Ю.
Θεματικοί όροι: ГИПЕРПЛАЗИЯ ЭНДОМЕТРИЯ, МАТРИКСНЫЕ МЕТАЛЛОПРОТЕИНАЗЫ, ЛЮКРИН-ДЕПО
Περιγραφή αρχείου: text/html
-
4Academic Journal
Συγγραφείς: Алексеев, Борис, Каприн, А., Нюшко, К.
Περιγραφή αρχείου: text/html
-
5Academic Journal
Συγγραφείς: Громова, Антоніна Макарівна, Громова, Антонина Макаровна, Gromova, A. M., Тарановська, Олена Олексіївна, Тарановская, Елена Алексеевна, Taranovska, O. O., Афанасьєва, Олена Євгеніївна, Афанасьева, Елена Евгеньевна, Afanasyeva, Е. E.
Θεματικοί όροι: гіперплазія ендометрія, агоністи гонадотропін-релізінг-гормонів, Люкри-депо, гиперплазия эндометрия, агонисты гонадотропин-релизинг-гормонов, Люкрин-депо, endometrial hyperplasia, gonadotrophin-releasing-hormone antagonists, Lucrin-depot
Περιγραφή αρχείου: application/pdf
Relation: Громова А. М. Сучасні аспекти лікування гіперпластичних процесів ендометрію / А. М. Громова, О. О. Тарановська, О. Є. Афанасьева // Актуальні проблеми сучасної медицини: Вісник української медичної стоматологічної академії. – 2009. – Т. 9. – № 2 (26). – C. 147–149.; https://repository.pdmu.edu.ua/handle/123456789/4809
Διαθεσιμότητα: https://repository.pdmu.edu.ua/handle/123456789/4809
-
6Academic Journal
Συγγραφείς: I. G. Rusakov, B. Ya. Alekseyev, K. M. Nyushko, И. Г. Русаков, Б. Я. Алексеев, К. М. Нюшко
Πηγή: Cancer Urology; Том 5, № 3 (2009); 56-60 ; Онкоурология; Том 5, № 3 (2009); 56-60 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2009-5-3
Θεματικοί όροι: Люкрин-депо, luteinizing hormone-releasing hormone agonists, Lucrin-depot, агонисты лютеинизирующего гормона рилизинг-гормона
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/267/284; Ries L.A.G., Kosary C.L., Hankey B.F. et al. SEER Cancer Statistics Review 1973—1995. Bethesda, MD: National Cancer Institute, 1998.; Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2009.; Матвеев В.Б. Клиническая онкоурология. М., 2003. с. 525—70.; Heidenreich A., Varga Z., Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2003; 169(3):1090.; Partin A.W., Kattan M.W., Subong E.N. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277(18):1445—51.; Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941;385—402.; Daneshgari F., Crawford E.D. Endocrine therapy of advanced prostate cancer. Cancer 1993;71:1089—97.; Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360(9327):103—8.; Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85—31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937—46.; Pilepich M.V., Winter K., John M.J. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50(5):1243—52.; Pilepich M.V., Winter K., Lawton C.A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma — long-term results of phase III RTOG 85—31. Int J Radiat Oncol Biol Phys 2005;61(5):1285—90.; Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472—9.; Seruga B., Tannock I.F. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008;5(10):574—6.; Labrie F., Belanger A., Dupont A. et al. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993;16(6):475—92.; Chrisp P., Sorkin E.M. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging 1991;1:487—509.; Sharifi R., Ratanwong C., Jung A., et al. Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv Drug Deliv Rev 1997;28:121—36.; Togushi H. Formulation study of leuprorelin acetate to improve clinical performance. Clin Ther 1992;14:121—30.; Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533—6.; Tunn U.W., Wiedey K. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis 2009;12(1): 83—7.; Berges R., Bello U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 2006;22(4):649—55.; Tunn U.W., Kurek R., Renneberg H. et al. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35(Suppl 1):27—31.; Gleave M.E., Goldenberg S.L., Chin J.L. et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166(2):500—6.; Soloway M.S., Pareek K., Sharifi R. et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002;167(1):112—6.; Montgomery B.S., Borwell J.P., Higgins D.M. Does needle size matters? Patient experience with luteinizing hormone releasing hormone analogue. Prostate Cancer Prostatic Dis 2005;8: 66—8.; Heyns C.F., Simonin M.P., Grosgurin P. et al. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003;92(3):226—31.; https://oncourology.abvpress.ru/oncur/article/view/267
-
7Academic Journal
Συγγραφείς: Русаков, И., Алексеев, Борис, Нюшко, К.
Θεματικοί όροι: РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, АГОНИСТЫ ЛЮТЕИНИЗИРУЮЩЕГО ГОРМОНА РИЛИЗИНГ-ГОРМОНА, ЛЮКРИН-ДЕПО
Περιγραφή αρχείου: text/html
-
8Academic Journal
Πηγή: Акушерство, гинекология и репродукция.
Περιγραφή αρχείου: text/html
-
9Academic Journal
Πηγή: Онкоурология.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ,ГОРМОНАЛЬНАЯ ТЕРАПИЯ,АНАЛОГИ ЛГРГ,ЛЮКРИН ДЕПО®, 3. Good health
Περιγραφή αρχείου: text/html
-
10Academic Journal
Πηγή: Онкоурология.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, 3. Good health, РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, АГОНИСТЫ ЛЮТЕИНИЗИРУЮЩЕГО ГОРМОНА РИЛИЗИНГ-ГОРМОНА, ЛЮКРИН-ДЕПО
Περιγραφή αρχείου: text/html
